本品由拜耳公司和Onyx公司联合开发,是首个口服多激酶抑制剂(multi-kinase inhibitor),靶向作用于肿瘤细胞和肿瘤脉管系统内的丝氨酸、苏氨酸和酪氨酸激酶受体。
基于1个网页-相关网页
目的合成一种新型的多激酶抑制剂。
索拉非尼是口服的多激酶抑制剂,可以抑制酪氨酸激酶受体,后者促进血管生成并在肾细胞癌中显示出高活性。
Sorafenib is an oral multikinase inhibitor with activity against tyrosine kinase receptors that are responsible for blood vessel development and has shown to be active in treating advanced RCC.
苏尼替尼是一种新型的多靶点酪氨酸激酶抑制剂。
Sunitinb is a novel multitargeted receptor tyrosine kinase inhibitor.
应用推荐